|
|
||||||||
From the Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX.
We evaluated pergolide in 22 patients with Parkinson's disease and 3 with progressive supranuclear palsy (PSP). After achieving an optimal dose of pergolide and Sinemet, a matching placebo was substituted in double-blind manner. The mean dose of levodopa (in Sinemet) was reduced by 68%; in eight patients, pergolide completely replaced levodopa. In parkinsonian patients, the mean Hoehn-Yahr stage decreased from 3.2 to 1.6, and the mean total disability score decreased from 48.3 to 17.8. In 10 patients with on-off phenomenon, the time on increased 174% with pergolide. There was little effect in PSP. Postural light-headedness and reversible mental changes were seen.
Address correspondence and reprint requests to Dr. Jankovic, Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX 77030.
Presented at the thirty-fourth annual meeting of the American Academy of Neurology, Washington, DC, April 1982.
Accepted for publication July 26, 1982.
This article has been cited by other articles:
![]() |
K. Kompoliti, C. G. Goetz, I. Litvan, K. Jellinger, and M. Verny Pharmacological Therapy in Progressive Supranuclear Palsy Arch Neurol, August 1, 1998; 55(8): 1099 - 1102. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |